Stevanato Group (NYSE:STVN) Raised to Strong-Buy at Wolfe Research

Stevanato Group (NYSE:STVN) was upgraded by analysts at Wolfe Research to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

STVN has been the subject of a number of other reports. Citigroup cut their price target on Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. Morgan Stanley cut their price target on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating for the company in a research note on Friday, March 6th. Jefferies Financial Group set a $17.50 price target on Stevanato Group in a research note on Tuesday, February 10th. KeyCorp cut their price objective on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a research note on Thursday, March 5th. Finally, Wall Street Zen downgraded Stevanato Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Stevanato Group has an average rating of “Moderate Buy”.

Stevanato Group Stock Up 0.7%

STVN opened at €18.92 on Monday. Stevanato Group has a fifty-two week low of €12.89 and a fifty-two week high of €28.00. The business has a 50-day moving average of €16.08 and a 200-day moving average of €17.88. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.63 and a quick ratio of 1.11. The company has a market capitalization of $5.73 billion, a PE ratio of 32.07, a price-to-earnings-growth ratio of 1.74 and a beta of 0.78.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings results on Friday, May 8th. The company reported €0.11 earnings per share for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). Stevanato Group had a return on equity of 10.27% and a net margin of 11.76%.The firm had revenue of €273.57 million for the quarter. During the same period in the previous year, the business earned $0.10 earnings per share. Stevanato Group’s quarterly revenue was up 6.6% on a year-over-year basis. Equities research analysts forecast that Stevanato Group will post 0.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Conestoga Capital Advisors LLC raised its stake in shares of Stevanato Group by 7.6% in the 1st quarter. Conestoga Capital Advisors LLC now owns 8,491,751 shares of the company’s stock valued at $116,762,000 after acquiring an additional 602,050 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of Stevanato Group by 10.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,923,632 shares of the company’s stock valued at $78,944,000 after acquiring an additional 368,792 shares in the last quarter. TimesSquare Capital Management LLC raised its stake in shares of Stevanato Group by 7.1% in the 4th quarter. TimesSquare Capital Management LLC now owns 3,500,321 shares of the company’s stock valued at $70,426,000 after acquiring an additional 232,645 shares in the last quarter. Bamco Inc. NY increased its position in Stevanato Group by 1.4% in the 4th quarter. Bamco Inc. NY now owns 2,001,724 shares of the company’s stock worth $40,275,000 after buying an additional 27,965 shares during the period. Finally, Jennison Associates LLC increased its position in Stevanato Group by 13.7% in the 4th quarter. Jennison Associates LLC now owns 1,772,896 shares of the company’s stock worth $35,671,000 after buying an additional 213,602 shares during the period.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.